Pfizer Inc. said Wednesday that an experimental breast cancer drug it is developing was more effective than an older therapy at slowing the progression of advanced breast cancer.
The US Food and Drug Administration (FDA) has approved Afinitor (everolimus) tablets for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ breast cancer) in combination with exemestane after failure of treatment with letrozole or anastrozole.